5 Results for "

JAR

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "JAR" in MCE Product Catalog:

6
6 Cited Publications
Cat. No.: HY-115521
CAS No.: 1212704-51-2
Purity:  99.17%
Target:  

Phytohormone

Research Areas:  

Others

Jarin-1 is a jasmonic acid-amido synthetase (JAR1) inhibitor with an IC50 of 3.8 μM. Jarin-1 specific inhibits bioactive JA (jasmonoyl-isoleucine, JA-Ile) biosynthesis in Arabidopsis and other plants .
loading...
    loading...
Cat. No.: HY-177782
Research Areas:  

Cancer

SB1349 is a molecular glucose degrading agent that targets the Lin28 protein. SB1349 can effectively induce proteasome dependent degradation of Lin28A and Lin28B. SB1349 can increase the level of mature let-7 miRNA, downregulate the oncogenes targeted by let-7, and effectively induce the differentiation of neuroblastoma cells. SB1349 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-18329
CAS No.: 787632-66-0
Target:  

MDM-2/p53 STAT Apoptosis

Research Areas:  

Cancer

TDP-665759 is an inhibitor for HDm2:p53 complex, and thus activates p53, inhibits STAT3 signaling pathway (EC50 of 5.90 μM) and the cell viability of p53 expressing A549R (IC50 of 7.02 μM). TDP-665759 induces apoptosis in HepG2. TDP-665759 exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-155237
Target:  

MicroRNA

Research Areas:  

Cancer

LIN28-IN-1 (compound 5) is an inhibitor of the RNA-binding and regulatory protein LIN28 and binds to the LIN28 cold shock domain (CSD). LIN28-IN-1 effectively inhibits the interaction between LIN28 and let-7 miRNA (IC50: 5.4 μM), blocking the negative impact of LIN28 on epigenetic gene regulation. LIN28-IN-1 significantly inhibits the proliferation of JAR cancer cells expressing LIN28 (IC50: 6.4 μM) .
loading...
    loading...
Cat. No.: HY-101266A
CAS No.: 1398569-75-9
Synonyms: DS-3032 tosylate
Target:  

MDM-2/p53

Research Areas:  

Cancer

Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC) .
loading...
    loading...